Societal Values and Health

  1. Mason H, Collins M, McHugh N, Godwin J, van Exel J, Donaldson C and Baker R (2018). Is “end of life” a special case? Connecting Q with survey methods to measure societal support for views on the value of life‚Äźextending treatments. Health Economics (early view). Link to open access paper:
  2. McHugh N, van Exel J, Mason H, Godwin J, Collins M, Donaldson C, Baker R (2018). Are life-extending treatments for terminal illnesses a special case? Exploring choices and societal viewpoints. Social Science and Medicine. 198:61-69 Link to open access paper:
  3. Mason H, van Exel J, Baker R, Brouwer W, Donaldson C, EuroVaQ Team (2016). From Representing Views to Representativeness of Views: illustrating a new (Q2S) approach in the context of health care priority setting in nine European Countries. Social Science and Medicine. 166:205-213. DOI: 10.1016/j.socscimed.2016.08.036
  4. van Exel J, Baker R, Mason H, Donaldson C, Brouwer W (2015) Public views on principles for health care priority setting: a European cross-country study using Q methodology Social Science & Medicine 126: 128-137
  5. McHugh N, Baker R, Mason H, Williamson L, van Exel NJA, Deogaonkar R, Collins M, Donaldson C (2015) Extending life for people with a terminal illness: a moral right and an expensive death? Exploring societal perspectives BMC Medical Ethics 16:14. Open access link:
  6. Pennington M, Baker R, Brouwer W, Mason H, Gyrd Hansen D, Robinson S, Donaldson C and the EuroVaQ Team (2015) Comparing WTP values of different types of QALY gain elicited from the general public Health Economics 24, 3: 280-293
  7. Jose-Luis Pinto-Prades, Fernando-Ignacio Sanchez-Martinez, Belen Corbacho, Rachel Baker (2014) Valuing QALYS at the End of Life Social Science & Medicine113: 5-14
  8. Baker R, Bartczak A, Chilton S, Metcalf H* (2014) Did people "buy" what was "sold"? A qualitative evaluation of a Contingent Valuation survey information set for gains in life expectancy Journal of Environmental Management 133: 94-103
  9. Lancsar E, Donaldson C, Louviere J, Currie G and Burgess L. Best Worst Discrete Choice Experiments in Health: Methods and an Application. Social Science and Medicine 2013; 76: 74-82.
  10. Collins M, Latimer N (2013). NICE's end of life decision making scheme: impact on population health. BMJ. 2013;346:f1363 doi:
  11. Emily Lancsar, John Wildman, Cam Donaldson, Mandy Ryan , Rachel Baker (2011) Deriving distributional weights for QALYs through discrete choice experiments Journal of Health Economics 30: 466-478
  12. Cam Donaldson, Rachel Baker, Helen Mason, Michael Jones-Lee, Emily Lancsar, John Wildman, Ian Bateman, Graham Loomes, Angela Robinson, Robert Sugden, Jose Luis Pinto Prades, Mandy Ryan, Phil Shackley and Richard Smith (2011)The social value of a QALY: raising the bar or barring the raise? BMC Health Services Research 11: 8
  13. Donaldson C. Willingness to pay and publicly-funded health care: contradictions in terms? Seminar Briefing No 10. Office of Health Economics, London, 2011.
  14. Mason H, Baker R and Donaldson C. Understanding public preferences for prioritising health care interventions in England: does the type of health gain matter? Journal of Health Services Research and Policy 2011; 16 81-89.
  15. Baker R, Chilton S, Donaldson C, Jones-Lee M, Lancsar E, Mason H, Metcalf H, Pennington M, Wildman J. Searchers versus surveyors in estimating the monetary value of a QALY: resolving a nasty dilemma for NICE. Health Economics, Policy and Law 2011; 6: 435-447.
  16. Rachel Baker, Ian Bateman, Cam Donaldson*, Michael Jones-Lee, Emily Lancsar, Graham Loomes, Helen Mason, Maria Odejar, Jose Luis Pinto Prades, Angela Robinson, Mandy Ryan, Phil Shackley, Richard Smith, Robert Sugden, John Wildman (2010) Weighting and valuing quality adjusted life years: preliminary results from the social value of a QALY project . HTA monograph. Health Technol Assess 14 : 27
  17. Mason H, Baker R M, Donaldson C (2009) Willingness to Pay for a QALY: past, present and the future Expert Reviews of Pharmacoeconomics and Outcomes Research 8, 6: 575-582
  18. Baker, R, Chilton, S M*, Jones-Lee, M W and Metcalf, H (2009) Valuing lives equally in a benefit-cost analysis of safety projects: a method to reconcile theory and practice. Safety Science 47, 6: 813-816
  19. Mason H, Jones-Lee MW and Donaldson C. (2009) Modelling the monetary value of a QALY: a new approach based on UK data. Health Economics; 18: 933-950
  20. Lamiraud K, Von Bremen K, Donaldson C. (2009) The impact of information on patient preferences in different delivery patterns: prescription versus OTC. Health Policy; 93: 102–110.
  21. Mason H, Jones-Lee M, Donaldson C (2009) Modelling the monetary value of a QALY: a new approach based on UK data. Health Economics. 18(8):933-950.
  22. Baker R, Chilton S, Jones-Lee M*, Metcalf H (2008) Valuing lives equally: defensible premise or unwarranted compromise? Journal of Risk and Uncertainty36, 2: 125-138
  23. Brouwer W, van Exel J, Baker R, Donaldson C (2008) The new myth: The social value of the QALY. PharmacoEconomics 26, 1: 1-4
  24. Baker R M, Robinson A, Smith R (2008) How do respondents explain ‘willingness to pay’ responses? A review of the qualitative evidence Journal of Socio-Economics 37, 4: 1427-
  25. Baker R, Chilton S*, Jones-Lee M, and Metcalf H (2007) A Face-Validity Test of Response Strategies to ‘Dread Risks’. Revue d'Economie Politique117, 5: 781-794